OGN News and Press, Organon & Co. From 06/10/22

The U.S. Food and Drug Administration (FDA) has for the first time required labeling changes to the popular anti-baldness pill Propecia marketed by Organon (NYSE:OGN) to reflect the risk of suicidal behavior in men taking the drug. Previously, the FDA has required labeling changes to the medi...

On One Year Anniversary, Organon Introduces Global Environmental, Social and Governance (ESG) Strategy and Commitments with Publication of Inaugural ESG Report Canada NewsWire Report lays out blueprint for achieving Organon's purpose and business imperatives to help wo...

Report lays out blueprint for achieving Organon’s purpose and business imperatives to help women and girls achieve their promise through better health Launch of Her Promise ESG platform creates a framework by which the company will advance innovation and progress in w...

Listen on the go! A daily podcast of Wall Street Breakfast will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks dipped into bear market territory on Friday, with the S&P 500's decline from its January all-time high hitting 20% at one point, before a late-s...

Pharmaceuticals and biotechnology are cheap relative to 11-year valuation averages. Life science tools and healthcare equipment are overvalued. IXJ: a global alternative to XLV. 10 stocks cheaper than their peers in May. For further details see: IXJ: Healthcare Dashb...

Bank of America upgraded the Israeli drugmaker Teva Pharmaceutical (NYSE:TEVA) to Neutral from Underperform on Tuesday, citing a shift in the attention to the company’s product portfolio following a potential countrywide opioid settlement. Teva (TEVA) ADRs have added ~3% in t...

One way to look at the immuno-oncology landscape over the last few years has been to think of it as The Quest for Synergy. And while there are indeed plenty of indications and plenty of targets yet to be explored, with plenty of antibodies for each, etc., what we've been seeing are so...

The following slide deck was published by Organon & Co. in conjunction with their 2022 Q1 earnings call. For further details see: Organon & Co. 2022 Q1 - Results - Earnings Call Presentation

Organon & Co (OGN) Q1 2022 Earnings Conference Call May 05, 2022, 08:30 ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO & Director Matthew Walsh - EVP & CFO Conference Call Participants Jason Gerberry - Bank of America Merrill Lynch Terence Flynn - Morgan Stanley...

Organon (NYSE:OGN), the Merck (MRK) spinoff focused on women’s health and biosimilars, is trading ~4% higher in the pre-market Thursday after reporting better than expected financials for Q1 2022 thanks to the outperformance of its established brands segment. After back-...